Emergent BioSolutions (EBS) Receivables (2010 - 2026)

Emergent BioSolutions' Receivables history runs 17 years deep, the most recent figure standing at $139.9 million for Q1 2026.

• On a quarterly basis, Receivables fell 40.37% year-over-year to $139.9 million in Q1 2026; TTM through Mar 2026 was $139.9 million, a 40.37% decrease from a year earlier, with the FY2025 full-year figure at $102.4 million, down 41.18% from the prior year.
• Receivables advanced to $139.9 million in Q1 2026 per EBS's latest filing, from $85.0 million in the prior quarter.
• Across five years, Receivables topped out at $341.9 million in Q2 2023 and bottomed at $85.0 million in Q4 2025.
• The 5-year median for Receivables is $230.1 million (2022), against an average of $209.8 million.
• Across the five-year window, Receivables soared 51.59% in 2023 and plunged 63.16% in 2025, its largest moves.
• Year by year, Receivables stood at $159.9 million in 2022, then surged by 51.59% to $242.4 million in 2023, then declined by 28.18% to $174.1 million in 2024, then slumped by 51.18% to $85.0 million in 2025, then soared by 64.59% to $139.9 million in 2026.
• Per Business Quant, the three latest EBS Receivables figures stand at $139.9 million (Q1 2026), $85.0 million (Q4 2025), and $168.8 million (Q3 2025).